Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

Delayed Quote. Delayed  - 08/24 10:00:00 pm
2.65 USD   -2.93%
08/04 GERON : reports 2Q loss
08/03 Geron Corporation Reports Second Quarter 2016 Financial Results a..
07/27 Geron Announces Conference Call to Discuss Second Quarter 2016 Fi..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/18/2016 08/19/2016 08/22/2016 08/23/2016 08/24/2016 Date
2.73(c) 2.72(c) 2.74(c) 2.73(c) 2.65(c) Last
723 832 780 930 933 460 662 927 2 152 472 Volume
0.00% -0.37% +0.74% -0.36% -2.93% Change
More quotes
Financials ($)
Sales 2016 1,30 M
EBIT 2016 -37,8 M
Net income 2016 -37,1 M
Debt 2016 -
Yield 2016 -
Sales 2017 47,7 M
EBIT 2017 12,9 M
Net income 2017 6,33 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 77,56
Capi. / Sales2016 334x
Capi. / Sales2017 9,10x
Capitalization 434 M
More Financials
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park,... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
08/04 GERON : reports 2Q loss
08/03 GERON CORP : Results of Operations and Financial Condition, Financial Statements..
08/03 GERON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
08/03 Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Ev..
07/27 Geron Announces Conference Call to Discuss Second Quarter 2016 Financial Resu..
07/13 Geron Announces Issuance of U.S. Patents Related to Imetelstat
05/06 GERON : reports 1Q loss
05/05 Geron Corporation Reports First Quarter 2016 Financial Results and Recent Eve..
04/27 Geron Announces Conference Call to Discuss First Quarter 2016 Financial Resul..
04/20 Geron Announces Two Imetelstat Poster Presentations at the American Associati..
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/07 Do Geron's Q2 Results Point To A Strong Close In 2016?
08/03 Geron's (GERN) CEO John Scarlett on Q2 2016 Results - Earnings Call Transcrip..
08/03 Geron beats by $0.02, misses on revenue
08/02 Notable earnings after Wednesday?s close
07/01 GERON : Announcing Imetelstat Patent Protection Through 2032
Advertisement
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Full-screen chart
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 7,50 $
Spread / Average Target 175%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Hoyoung Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Independent Director
Robert Jay Spiegel Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION-43.60%434
AMGEN, INC.7.44%130 514
GILEAD SCIENCES, INC.-19.49%107 513
CELGENE CORPORATION-4.80%88 371
REGENERON PHARMACEUTIC..-22.52%44 288
VERTEX PHARMACEUTICALS..-19.74%25 023
More Results